ES2687756T3 - Sal de un compuesto de morfolina - Google Patents

Sal de un compuesto de morfolina Download PDF

Info

Publication number
ES2687756T3
ES2687756T3 ES07790605.5T ES07790605T ES2687756T3 ES 2687756 T3 ES2687756 T3 ES 2687756T3 ES 07790605 T ES07790605 T ES 07790605T ES 2687756 T3 ES2687756 T3 ES 2687756T3
Authority
ES
Spain
Prior art keywords
compound
dichlorobenzyl
morpholin
methyl
ylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07790605.5T
Other languages
English (en)
Spanish (es)
Inventor
Katsuhiko Masuda
Shuzo Takeda
Yoshihito Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ES2687756T3 publication Critical patent/ES2687756T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES07790605.5T 2006-07-11 2007-07-11 Sal de un compuesto de morfolina Active ES2687756T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006190437 2006-07-11
JP2006190437 2006-07-11
PCT/JP2007/063801 WO2008007691A1 (en) 2006-07-11 2007-07-11 Salt of morpholine compound

Publications (1)

Publication Number Publication Date
ES2687756T3 true ES2687756T3 (es) 2018-10-29

Family

ID=38923247

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07790605.5T Active ES2687756T3 (es) 2006-07-11 2007-07-11 Sal de un compuesto de morfolina

Country Status (6)

Country Link
US (1) US8030303B2 (enExample)
EP (1) EP2042499B1 (enExample)
JP (2) JP5501615B2 (enExample)
ES (1) ES2687756T3 (enExample)
TW (1) TWI399375B (enExample)
WO (1) WO2008007691A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030303B2 (en) * 2006-07-11 2011-10-04 Mitsubishi Tanabe Pharma Corporation Salt of morpholine compound
US10130634B2 (en) 2013-07-24 2018-11-20 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for ophthalmic disease
WO2020203822A1 (ja) * 2019-03-29 2020-10-08 千寿製薬株式会社 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
MEP5808A (xx) * 2002-12-23 2010-02-10 Lundbeck & Co As H Ecitalopram bromhidrat i postupak za njegovo pripremanje
IN2014CN03493A (enExample) * 2004-09-08 2015-07-03 Mitsubishi Tanabe Pharma Corp
KR101137880B1 (ko) 2004-12-31 2012-04-20 엘지디스플레이 주식회사 쉬프트 레지스터 및 그 구동 방법
US8030303B2 (en) * 2006-07-11 2011-10-04 Mitsubishi Tanabe Pharma Corporation Salt of morpholine compound

Also Published As

Publication number Publication date
JPWO2008007691A1 (ja) 2009-12-10
EP2042499A4 (en) 2009-10-21
US20090264430A1 (en) 2009-10-22
TWI399375B (zh) 2013-06-21
TW200817392A (en) 2008-04-16
EP2042499B1 (en) 2018-06-27
JP5501615B2 (ja) 2014-05-28
JP2014015489A (ja) 2014-01-30
US8030303B2 (en) 2011-10-04
WO2008007691A1 (en) 2008-01-17
EP2042499A1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
ES2547153T3 (es) Derivados de 8-alcoxi-aminotetralina sustituidos y su uso
ES2382806T3 (es) Compuesto ácido ciclohexanocarboxílico
BR112014010169B1 (pt) Compostos de derivado n-tienilbenzamida substituída com aminoalquil, composição contendo os ditos compostos e uso dos mesmos para prevenir ou tratar hiperfosfatemia
AU777569B2 (en) Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
NO318388B1 (no) Indano-dihydrotiazolderivater, deres anvendelse, legemidler omfattende disse og en fremgangsmate for fremstillimg av legemidlene.
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
ES2687756T3 (es) Sal de un compuesto de morfolina
ES2284926T3 (es) Nuevos compuestos de feniltanolaminas con una funcion de exticion de un receptor beta2 y metodo para su preparacion.
KR20150036081A (ko) 카르바메이트/우레아 유도체
ES3011357T3 (en) Hydrochloride salt 1.5 hydrate of an heterocyclic derivative compound
AU2010271746A1 (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
KR20200081359A (ko) 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태
JPH093066A (ja) クロモン誘導体
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
TW200934774A (en) Arylmethylidene heterocycles as novel analgesics
CA3196061A1 (en) Cftr modulator compounds, compositions, and uses thereof
JP2018127429A (ja) インドール酢酸アミド誘導体
TW201206910A (en) Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
PT1937248E (pt) AMIDAS DE áCIDOS ALCANËICOS SUBSTITUDAS POR O-HETEROCICLOS SATURADOS
CA2511021C (en) Substituted benzodioxepines
JPWO2011145548A1 (ja) ジ（アリールアミノ）アリール化合物の結晶
WO2019006335A1 (en) INHIBITORS OF HIV-1 PROTEASE AND USES THEREOF
AU765300B2 (en) Polycyclic thiazole-2-ylides amines, method for the production thereof and their utilization as medicaments
JPWO2014196644A1 (ja) ベンゾチオフェン化合物
AU2010305834A1 (en) Polymorphs of pardoprunox